Vomiting News and Research

RSS
Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.
Calcium-sensing receptor plays key role in lethal lung cancer complication

Calcium-sensing receptor plays key role in lethal lung cancer complication

GE Healthcare announces results of Optison heart ultrasound contrast agent presented at ASE

GE Healthcare announces results of Optison heart ultrasound contrast agent presented at ASE

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Eli Lilly, Synthes collaborate to develop osteoinductive products

Eli Lilly, Synthes collaborate to develop osteoinductive products

Drop in flu vaccination rates alarms health authorities

Drop in flu vaccination rates alarms health authorities

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium reports results from two VELCADE based combination studies against multiple myeloma

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

EC approves Biogen Idec's AVONEX PEN to treat multiple sclerosis

EC approves Biogen Idec's AVONEX PEN to treat multiple sclerosis

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.